ImmunityBio (IBRX) Q4 2025 earnings summary

Executive summary

• Achieved a transformational year with $113 million in net product revenue for Anktiva in 2025, a 700% year-over-year increase and 750% rise in unit sales volume, driven by strong clinical adoption and international expansion.

• Anktiva is now authorized in 33 countries, including the U.S., U.K., Saudi Arabia, and the EU, with the first global approval for lung cancer in Saudi Arabia.

• The company is executing a multi-platform immunotherapy strategy, advancing CAR-NK cell and DNA vaccine platforms, and positioning Anktiva as the backbone of the Cancer BioShield platform with over 30 active and planned clinical trials across 10 tumor types.

• Established commercial partnerships in the EU and MENA regions, deploying over 100 sales professionals and launching subsidiaries in Dublin and Saudi Arabia.

• Significant progress in clinical trials and regulatory milestones, including approvals for bladder and lung cancer indications.

Financial highlights

• Net product revenue reached $113 million in 2025, up from $14.1 million in 2024, with a 750% increase in unit sales volume.

• Q4 2025 revenue grew 20% sequentially from Q3 and reached $38.3 million, a 431% increase year-over-year.

• Full year R&D expenses were $218.6 million, up from $190.2 million, including a $14 million one-time fixed asset write-off.

• SG&A expenses decreased to $150 million from $168.8 million, due to internal team expansion and reduced consulting.

• Net loss narrowed to $351.4 million from $413.6 million in 2024.

• Year-end cash, equivalents, and marketable securities totaled $242.8 million.

Outlook and guidance

• No forward financial guidance provided.

• Focused on expanding Anktiva's label to BCG-naïve bladder cancer and international lung cancer indications, with BLA submission for BCG-naïve bladder cancer targeted for Q4 2026.

• Planning accelerated approval submissions for lung cancer and multiple tumor types in 2026.

• Preparing for commercial launches in Europe and Saudi Arabia, with Germany and Saudi as initial focus markets.

• Ongoing development of AI-driven manufacturing and operational platforms to support global expansion.